Molecular/Cancer Biology, Research Programs Unit, Biomedicum Helsinki, P.O.B. 63, (Haartmaninkatu 8), FIN-00014, University of Helsinki, Finland.
Trends Mol Med. 2011 Jul;17(7):347-62. doi: 10.1016/j.molmed.2011.01.015. Epub 2011 Apr 12.
Solid tumors require blood vessels for growth and dissemination, and lymphatic vessels as additional conduits for metastatic spread. The identification of growth factor receptor pathways regulating angiogenesis has led to the clinical approval of the first antiangiogenic molecules targeted against the vascular endothelial growth factor (VEGF)-VEGF receptor (VEGFR)-2 pathway. However, in many cases resistance to anti-VEGF-VEGFR therapy occurs, and thus far the clinical benefit has been limited to only modest improvements in overall survival. Therefore, novel treatment modalities are required. Here, we discuss the members of the VEGF-VEGFR family as well as the angiopoietin growth factors and their Tie receptors as potential novel targets for antiangiogenic and antilymphangiogenic therapies.
实体瘤的生长和扩散需要血管，而淋巴管则是转移扩散的另一种途径。识别生长因子受体通路调节血管生成，导致了针对血管内皮生长因子 (VEGF)-VEGF 受体 (VEGFR)-2 通路的首个抗血管生成分子的临床批准。然而，在许多情况下，会对抗 VEGF-VEGFR 治疗产生耐药性，到目前为止，临床获益仅限于总体生存的适度改善。因此，需要新的治疗方式。在这里，我们讨论了 VEGF-VEGFR 家族成员以及血管生成素生长因子及其 Tie 受体作为抗血管生成和抗淋巴管生成治疗的潜在新靶点。
